Factors associated with HER2 overexpression in breast cancer: Experience in an Asian developing country

Asian Pacific Journal of Cancer Prevention

Volumn 10, Issue 5, 2009, Pages 837-840

  Tan, Gie Hooi ^a   Choo, Wan Yuen ^b   Taib, Nur Aishah ^a   Yip, Cheng Har ^a  

^a UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^b UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Breast cancer; clinicopathological factors; HE2 overexpression

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASIAN; BREAST TUMOR; CANCER STAGING; DEVELOPING COUNTRY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DEVELOPING COUNTRIES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77952317134     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Ariga R, Zarif A, et al, (2005). Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J, 11, 278-80.
2. Bilous M, Ades C, et al (2003). Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study. Breast, 12, 92-8.
3. Borg A, Tandon AK, et al (1990). HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res, 50, 4332-7.
4. Coussens L, Yang-Feng TL, et al (1985). Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science, 230, 1132-9.
5. Greene FL, Fleming ID et al (2002). AJCC Cancer Staging Manual 6th Ed. New York. Springer.
6. Looi LM, Cheah PL (1998). C-erbB-2 oncoprotein amplification in infiltrating ductal carcinoma of breast relates to high histological grade and loss of oestrogen receptor protein. Malays J Pathol, 20, 19-23.
7. Marti JL, Guth A, et al (2008). Receptor status and ethnicity of indigent patients with breast cancer in New York City. Arch Surg, 143, 1227-30.
8. Menard S, Balsari A, et al (2002). HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin Cancer Res, 8, 520-5.
9. Mittra I, Redkar AA, et al (1995). Prognosis of breast cancer: evidence for interaction between c-erbB-2 overexpression and number of involved axillary lymph nodes. J Surg Oncol, 60, 106-11.
10. Schechter AL, Hung MC, et al (1985). The neu gene: an erbBhomologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science, 229, 976-8.
11. Selvarajan S, Wong KY, et al, (2006). Over-expression of c-erbB-2 correlates with nuclear morphometry and prognosis in breast carcinoma in Asian women. Pathology, 38, 528-33.
12. Slamon DJ, Clark GM, et al, (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82.
13. Stark A, Kapke A, et al, (2008). Advanced stages and poorly differentiated grade are associated with an increased risk of HER2/neu positive breast carcinoma only in White women: findings from a prospective cohort study of African-American and White-American women. Breast Cancer Res Treat, 107, 405-14.
14. Supanaranond K, Sukarayodhin S, et al, (1997). The significance of HER-2/neu/c-erbB-2 gene amplification in benign and malignant breast disease. Southeast Asian J Trop Med Public Health, 28, 631-40.
15. Tandon AK, Clark GM, et al, (1989). HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol, 7, 1120-8.
16. Wolff AC, Hammond ME, et al, (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol, 25, 118-45.
17. Yau TK, Sze H, et al, (2008). HER2 overexpression of breast cancers in Hong Kong: prevalence and concordance between immunohistochemistry and in-situ hybridisation assays. Hong Kong Med J, 14, 130-5.